Compare PDS & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PDS | CMPX |
|---|---|---|
| Founded | 1951 | 2014 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 918.1M | 752.4M |
| IPO Year | N/A | N/A |
| Metric | PDS | CMPX |
|---|---|---|
| Price | $68.38 | $5.08 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $98.00 | $13.44 |
| AVG Volume (30 Days) | 76.5K | ★ 1.9M |
| Earning Date | 10-22-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.98 | N/A |
| Revenue | ★ $1,316,232,437.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.89 | N/A |
| P/E Ratio | $23.04 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $36.20 | $1.33 |
| 52 Week High | $71.77 | $5.86 |
| Indicator | PDS | CMPX |
|---|---|---|
| Relative Strength Index (RSI) | 67.77 | 52.34 |
| Support Level | $56.10 | $5.09 |
| Resistance Level | $71.77 | $5.44 |
| Average True Range (ATR) | 2.29 | 0.34 |
| MACD | 0.49 | -0.07 |
| Stochastic Oscillator | 77.87 | 31.42 |
Precision Drilling Corp is a provider of contract drilling and completion and production services to oil and natural gas exploration and production companies in Canada, the United States, and certain international locations. Contract Drilling Services include drilling rigs, procurement and distribution of oilfield supplies, and the manufacture, sale and repair of drilling equipment. Completion and Production Services include service rigs, oilfield equipment rental, and camp and catering services.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.